期刊文献+

小檗碱对改善大鼠动脉粥样硬化的影响及作用机制 被引量:3

The effects and mechanism of action on Berberine to Atherosclerosis in rats
下载PDF
导出
摘要 目的:研究小檗碱对大鼠动脉粥样硬化的影响,并阐明其机制。方法:将30只大鼠随机分为5组,只饲基础饲料组作空白对照组(A),模型组(B)不予给药,C、D、E组给予不同剂量小檗碱,测定大鼠血液中TC、TG、LDL-C和HDL-C浓度,以及SOD活性和MDA水平。结果:给药大鼠与模型组相比较,TC、TG、LDL-C浓度明显降低(P<0.05),HDL-C浓度升高(P<0.05),SOD活性增强,MDA水平降低(P<0.05),SOD与MDA呈负相关。结论:小檗碱具有改善大鼠动脉粥样硬化的功效,可作为降血脂药应用于临床。 Objective: To study the effects on Berberine to Atherosclerosis in rats, and illustrate the mechanism of action. Methods :The 30 rats were divided them into five groups randonfly,the control group was gived basic feed only, the model group wasn't gived dntgs,C,D,E group were gived different dose of Berberine,determined the concentration of TC,TG,LDL-C and HDL-C in rats blood. Determined the activity of SOD and level of MDA. Results:The treatment groups were compared with model group,The concentration of TC,TG,LDL-C were declined obviously(P〈0.05).The concentration of HDL-C was inereased(P〈0.05),file activity of SOD was strengthen,the level of MDA was declined (P〈0.05),SOD and MDA were negative cobb'elation . Concluslons:The Berberine can improve the symptom of atheroselerosis in rats, and can be used as a Lowering blood IApids drug in clinic.
作者 石军飞 闫超
出处 《北方药学》 2012年第11期27-28,共2页 Journal of North Pharmacy
关键词 小檗碱 动脉粥样硬化 Berberine Atherosclerosis
  • 相关文献

参考文献2

二级参考文献10

共引文献48

同被引文献53

  • 1Flora Affuso,Valentina Mercurio,Valeria Fazio,Serafino Fazio.Cardiovascular and metabolic effects of Berberine[J].World Journal of Cardiology,2010,2(4):71-77. 被引量:11
  • 2吕医瑞,张玉平,曹荣辉,李建军.小檗碱改善血脂抗动脉粥样硬化机制进展[J].中国动脉硬化杂志,2015,23(4):427-432. 被引量:12
  • 3Ikekawa,T,lkeda. Antitumor activity of 13 -methyl -berberrubine derivatives [J]. J Pharmaeobiodyn, 1982, 5 (7) : 469-474.
  • 4Iwasa K,Kamigauchi M ,Sugiura M ,et al. Antimicrobial activity of some 13-alkyl substituted protoberberinium salts [J]. Planta Med, 1997,63(3) : 196-198.
  • 5Park KD,Lee JH,Kim SH,et al. Synthesis of 13-(substituted ben- zyl) berberine and berbermbine derivatives as antifungal agents [J]. Bioorg Med Chem Lett, 2006,16 ( 15 ) : 3913-3916.
  • 6Li X,Zhao WL,Jiang JD,et al. Synthesis, structure-activity relation- ship and biological evaluation of anticancer activity for novel N- substituted sophoridinic acid derivatives [J]. Binorg Med Chem Lett, 2011,21 (18) :5251-5254.
  • 7Zhao W,He H,Ren K,et al. MR-I blocks the megakaryocytic dif- ferentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation [J]. Blood Cancer J ,2013,3(2) : 107.
  • 8Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin[J]. Science, 2005, 307(5708) :426.
  • 9Filippatos T D, Randeva H S, Derdemezis C S, et al. Visfatin/PBEF and atheroselerosis'-related diseases [ J]. Curt Vase Pharmacol, 2010, 8(1 ) :12.
  • 10Adya R, Tan B K, Chen J, et al. Nuclear factor- kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation[J]. Diabetes Care,2008, 31 (4) :758.

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部